Flunixin Meglumine Injection

Description

Product Description: Flunixin Meglumine Injection is a meticulously formulated pharmaceutical solution designed to provide potent analgesic and anti-inflammatory effects in veterinary medicine. It contains flunixin meglumine, a nonsteroidal anti-inflammatory drug (NSAID) known for its efficacy in managing pain and inflammation in horses, cattle, and swine. Manufactured to the highest quality standards, this injection offers fast and reliable relief from pain and inflammation associated with various conditions.

Indications and Usage: Flunixin Meglumine Injection is indicated for the alleviation of pain and inflammation associated with musculoskeletal disorders, respiratory diseases, and colic in horses, cattle, and swine. It is particularly useful in situations where oral administration is not feasible or when rapid relief is needed.

Dosage and Administration: The dosage of Flunixin Meglumine Injection varies depending on the species, age, weight, and the severity of symptoms. It is typically administered via intravenous or intramuscular route under the guidance of a veterinarian. Dosage adjustments may be necessary based on the animal's response to therapy and individual tolerance.

Dosage Forms and Strengths: Flunixin Meglumine Injection is available as a sterile solution in vials containing specific concentrations of flunixin meglumine formulated for parenteral administration. Each vial is carefully manufactured to ensure accurate dosing and optimal therapeutic outcomes.

Contraindications: This product is contraindicated in animals with a known hypersensitivity to flunixin meglumine or any of the excipients. It should not be used in animals with preexisting renal dysfunction, gastrointestinal ulceration, or coagulation disorders. Additionally, it is contraindicated in pregnant or lactating animals.

Warnings and Precautions: Veterinarians should exercise caution when prescribing Flunixin Meglumine Injection to animals with a history of gastrointestinal disorders, hepatic impairment, or cardiac disease. Prolonged use may increase the risk of gastrointestinal ulceration, renal toxicity, and coagulation abnormalities. Animals should be monitored closely for signs of these adverse effects during therapy.

Adverse Reactions/Side Effects: Common adverse reactions associated with Flunixin Meglumine Injection include gastrointestinal disturbances such as diarrhea, colic, and gastric ulcers. Rarely, serious adverse effects such as renal failure, hepatic dysfunction, and hematological abnormalities may occur. Animals should be assessed regularly for any signs of adverse reactions.

Drug Interactions: Concomitant use of Flunixin Meglumine Injection with other NSAIDs, corticosteroids, or nephrotoxic drugs may increase the risk of gastrointestinal ulceration or alter the pharmacokinetics of flunixin. Veterinarians should review the animal's medication profile carefully to avoid potential drug interactions.

Use In Specific Populations Description: Safety and efficacy of Flunixin Meglumine Injection in pregnant or lactating animals have not been established conclusively. Veterinarians should assess the potential risks and benefits before prescribing this medication in these populations.

How Supplied/Storage and Handling: Flunixin Meglumine Injection is supplied as a sterile solution in vials for parenteral administration. It should be stored at controlled room temperature away from light and moisture. Care should be taken to avoid freezing or excessive heat exposure. Unused portions should be discarded according to standard procedures for biohazardous waste.